indolent lymphoma
Information
- Disease name
- indolent lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04806035 | Active, not recruiting | Phase 1 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | April 23, 2021 | December 1, 2024 |
| NCT03133221 | Active, not recruiting | Phase 2 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | October 23, 2017 | March 2025 |
| NCT04431635 | Active, not recruiting | Phase 1 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | June 15, 2020 | June 2026 |
| NCT03424603 | Completed | Phase 1 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | February 22, 2018 | March 15, 2024 |
| NCT00980395 | Completed | Phase 2 | Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | July 7, 2009 | August 14, 2018 |
| NCT01263899 | Completed | Phase 2 | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | December 2010 | February 2012 |
| NCT05543070 | Recruiting | Phase 2 | Low-dose Radiotherapy in iNHL | May 1, 2022 | January 1, 2025 |
| NCT04957693 | Recruiting | N/A | Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period | July 5, 2021 | October 1, 2025 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT00954005 | Terminated | Phase 1/Phase 2 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma | January 2003 | June 2012 |
| NCT00687778 | Unknown status | 11C-Acetate PET/CT Non-FDG-Avid Tumors | May 2008 | June 2010 | |
| NCT05003141 | Unknown status | Phase 1 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | November 15, 2021 | January 2024 |
| NCT03261349 | Unknown status | Phase 2 | Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | September 1, 2017 | August 15, 2021 |